Dr. Wu is a chair professor and dean of the School of Life Sciences at Peking University, and a senior investigator of the Peking-Tsinghua Center for Life Sciences. Before returning to China, Dr. Hong Wu was David Geffen Professor of Molecular and Medical Pharmacology and director of the Institute for Molecular Medicine at the David Geffen School of Medicine at UCLA.
Dr. Wu received her medical training from Beijing Medical College, China, and her PhD in Biological Chemistry from Harvard Medical School. After postdoctoral training as a Damon Runyon-Walter Winchell postdoctoral fellow at the Whitehead Institute for Biomedical Research, MIT, she joined UCLA as a faculty member.
A major research focus of Dr. Wu's laboratory is to study the molecular mechanism of PTEN tumor suppressor controlled tumorigenesis. By generating tissue-specific PTEN deficient animal models, Dr. Wu's laboratory elucidated the important role of PTEN in regulating stem cell self-renewal, proliferation, and survival, as well as its roles in controlling the PI3K pathway. These models have been used for preclinical studies of new therapeutic agents and for identifying biomarkers for human prostate cancers.

1978-1983: Medical education - Beijing Medical College, Beijing, P. R. China; Bachelor of Medicine; received in July 1983.
1984-1991: Graduate education - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;
and Whitehead Institute for Biomedical Research, Cambridge, MA; Ph.D. received in June 1991; Mentor: Dr. Rudolf Jaenisch
1991-1992: Postdoctoral training - Whitehead Institute for Biomedical Research, Cambridge,
Massachusetts. Mentor: Dr. Rudolf Jaenisch
1993-1996: Post-doctoral training - Whitehead Institute for Biomedical Research, Cambridge,
Massachusetts. Mentor: Dr. Harvey F. Lodish

1996-2013: Assistant Professor to Full Professor
Department of Molecular and Medical Pharmacology
Members, Jonsson Comprehensive Cancer Center and Molecular Biology Institute,
University of California, Los Angeles
1997-2004: Assistant Investigator
Howard Hughes Medical Institute
2003-2012: Director
Molecular and Genetic Technology Center
University of California, Los Angeles
2004-2013: Associate Director
Genitourinary Oncology Program Area, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
2006-2013: Co-Director
Cancer Stem Cell Program
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
University of California, Los Angeles
2008-2011: Associate Director for Research
Institute for Molecular Medicine
Vice Chair
Department of Molecular and Medical Pharmacology
David Geffen School of Medicine, University of California, Los Angeles
2009-2013: David Geffen Chair in Medical Research
David Geffen School of Medicine, University of California, Los Angeles
2011-2013: Director
Institute for Molecular Medicine
David Geffen School of Medicine, University of California, Los Angeles
2013-2023: Dean and chair professor
School of Life Sciences
Peking University
2013-present: Chair professor
School of Life Sciences
Peking University
2013-present: Senior Investigator
PKU-Tsinghua Center for Life Sciences
Peking University
2013-2022: Recalled Professor without salary
David Geffen School of Medicine, University of California, Los Angeles
2019-2023: Associate Director
Shenzhen Bay Laboratory
2019-present: Senior Investigator
Shenzhen Bay Laboratory
2021-present: Chair, Academic Senate
Yan Yuan Academy
Peking University
2021-present: Member, Council
Peking University Education Foundation
Peking University
2022-present: Member, Academic Senate
Peking Univerviery
2023-present: Chair, Academic Senate
School of Life Sciences
Peking University

2023 Student Favorite Teacher Award, School of Life Sciences, PKU
2023 Outstanding Research Award, School of Life Sciences, PKU
2021 Science & Technology Award, Beijing City
2016 Associate Member, EMBO
2013 Chair Professor, Peking University
2011 Fellow of American Association for the Advancement of Science
2009 David Geffen Endowed Chair for Medical Research
2008 Adelson Foundation Award
2008 Prostate Cancer Foundation Award
2006 Brain Tumor Society Program Award
2006 Waxman Foundation Program Award
2004 Prostate Cancer Foundation Award
2003 James S. McDonnell Foundation Award
2002 The Brain Tumor Society Award
2000 CaPCure Research Award
2000 1999 Cheryl Whitlock Memorial Prize, Palo Alto, CA
7/1997 - 8/2004 Howard Hughes Assistant Investigator Award, Chevy Chase, Maryland
6/1997 - 5/1999 The V Foundation Scholar Award, Cary, North Carolina
5/1997 - 4/2001 Pew Scholar Award (relinquished due to the duplication with the HHMI Award), San Francisco, California
7/1996 Stop Cancer-Next Generation Award, Los Angeles, California
11/1992 -10/1995 Damon Runyon-Walter Winchell Postdoctoral Fellowship, New York, NY
5/1991 Radcliffe Grant for Graduate Women, Harvard, University, Cambridge, MA
6/1985 - 5/1990 Lucille P. Markey Fellowship, Harvard Medical School, Boston, MA
7/1984 - 6/1987 CUSBEA exchange studentship, Harvard Medical School and CUSBEA Program
9/1978 - 7/1983 Highest Honors, Beijing Medical College, Beijing, P.R.China

UCLA

1997 Graduate student advisor for MCDB
1997 Graduate admission committee for MCDB
1998 Pharmacology Faculty Search Committee
1999 Co-chair, Pharmacology Seminar Series
1998-2003 Committee on School of Medicine Lecture
1998-2005 Committee on Graduate Training, MMP
1998 CMB Training Grant Committee
1999 ACCESS Recruit Committee
1998-2013 Committee on the Vivarium
1998-2013 Rodent User Oversight Committee
2000 Co-chair, Pharmacology Seminar Series
2000 MMI Faculty Search Committee
2001-2003 Director for Cancer Center ES cell Core Facility
2002-2007 MBI Seminar Committee
2003-2012 Director of the UCLA ES and Transgenic Center
2004-2013 UCLA Institute of Stem Cell Biomedical Sciences working group
2006-2013 Co-director, Cancer Stem Cells and GU-Prostate Cancer Program areas
2006 Chair, UCLA SPORE developmental grant review committee
2007-2013 Faculty Advisory Committee for the Minor in Biomedical Research
2008-2011 Associate Director for Research, Institute for Molecular Medicine, UCLA
2011-2013 Director, Institute for Molecular Medicine, UCLA

Peking University

2013-2023 Vice chair, Academic Senate, School of Life Sciences
2013-2023 Member, Academic Sanate, Center for Life Sciences
2014-present PKU correspondent, PKU-Bayer strategical collaboration
2017-present PKU correspondent, PKU-Boehringer Ingelheim strategical collaboration
2017-present Chair, Board of Directors, PKU-East China Biotechnology Institute
2021-present Chair, Academic Senate, Lan Yuan Academy
2021-present Member, PKU Education Foundation Council
2022-present Member, Academic Senate, Peking University
2023-present Chair, Academic Senate, School of Life Sciences

Others

1999 Organizer and section chair, the US National Academy of Sciences Committee
for American-Chinese Frontier of Sciences, Beijing (1999) Irvine, CA (2000)
1999 Steering committee member, Mouse Model of Human Cancer Consortium, NCI (1999-2004).
2000 Ad hoc reviewer, Michigan Life Sciences Corridor Fund
2001 Section Co-chair, Frontiers of Biological Sciences in the 21st Century, Beijing, P.R.China
2002 Section Co-chair, The Ray Wu Society meeting, San Diego, CA
2003 Panelist, The Chinese National Science Foundation Review Committee (2003-2005)
2004 Co-organizer, NCI-MMHCC semi-annual meeting, Los Angeles, CA
2004 Co-organizer, The 1st International Meeting on PTEN Tumor Suppressor Gene, Arizona
2004 Panelist, The Chinese National Science Foundation Review Committee for Medicine (2004-2008)
2004 Steering committee member and chair, the prostate cancer organ site committee, Mouse Model of Human Cancer Consortium, NCI (2004-2009).
2005 Member, Scientific Review Board, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences.
2006 Member of the board directors and Secretary General, The Chinese Biomedical Investigators Society (2006-2008).
2007 Member of the external advisor board, Roswell Park Cancer Institute (2007)
2007 Member and co-Chair, Honors and Awards Committee, Chinese-American Engineers and Scientists Association of Southern California.
2007 Co-Chair, subcommittee of the 2007 American Association for Cancer Research (AACR) Program Committee
2007 Organizer, Frontiers of Biomedical Sciences Symposium, Beijing, China
2008 Section chair, mTOR Signaling: From Cancer to CNS Function, Bethesda, MD
2008 Organizer and section chair: An AACR-ASH joint workshop on PI3-Kinase: A Common Pathway for Hematologic Malignancies and Solid Tumors. Lansdowne, VA
2008 Member, Scientific Review Board, Chinese Academy of Sciences (2008-2013)
2008 Member of the board directors, Ray Wu Memorial Foundation (2008-2012)
2009 Organizer and section co-chair, 2009 NCI Translational Medicine Meeting, VA
2011 Member of steering committee, NCI Tumor Microenvironment Consortium (2011-2016)
2012 Member of review committee, the Cancer Prevention and Research Institute of Texas (CRRIT)
2013 Member of Global Advisory Board, Movember (2013-2016)
2013 Member of International Affair Committee, AACR (2013-2020)
2014 Director of the Oversea Talent Biomedical Research Branch (2014-2016)
2015 Member of MOE Science and Technology Committee (2015-2020)
2019 Vice chair, Academic Senate, Shenzhen Bay Laboratory (2019-present)
2019 Associate director, Shenzhen Bay Laboratory (2019-2023)
2022 Chair, Selection Committee in Life Sciences, Asian Young Scientist Award
2022 Member, AACR Asian/Asian American Task Force (2022-now)
2023 Chair, Steering Committee, Asian Young Scientist Award, and member of Selection Committee in Life Sciences

2023 Chair, Steering Committee, Asian Young Scientist Award, and member of Selection Committee in Life Sciences
2022 Chair, Selection Committee in Life Sciences, Asian Young Scientist Award

INVITED SPEAKER

06/1991 Gordon Research Conferences on Collagens, NH

05/1992 Conference on Osteogenesis Imferfecta, Bethesda, MD
07/1992 NIH meeting “Program of Excellence”, Baltimore, MD

03/1995 Department of Pharmacology, University of Washington, Seattle, WA
04/1995 Department of Genetics, Duke University Medical School, NC
08/1995 Gordon Research Conferences on Red Cells, Plymouth, NH
10/1995 Department of Molecular and Cell Biology, Harvard University, MA
11/1995 Department of Pharmacology, Rutgers University, NJ
12/1995 American Society of Hematology, Seattle, WA
12/1995 Center for Advanced Biotechnology and Medicine, Rutgers University, NJ
12/1995 Department of Pathology and Molecular Pharmacology, Albert Einstein College of Medicine, NY

01/1996 Department of Molecular and Cell Biology, University of California, Berkeley, CA
01/1996 Department of Biological Sciences, Stanford University, CA
01/1996 DNAX, Palo Alto, CA
01/1996 Department of Cell Biology and Anatomy, Johns Hopkins University, MD
02/1996 Department of Molecular Medicine, Beth Israel Hospital, Harvard Medical School, MA
02/1996 Institute of Biotechnology/Center for Molecular Medicine, The University of Texas Health Science Center at San Antonio, TX
02/1996 Department of Pathology, Harvard Medical School, Boston, MA
02/1996 Department of Biology, Princeton University, NJ
02/1996 JCCC Cancer Center, University of California, Los Angeles, CA
03/1996 Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, MA
04/1996 Department of Cell Biology, Duke University Medical School, NC
04/1996 Department of Physiology, University of California, San Francisco, CA
07/1996 Institute of Basic Medical Sciences, Beijing, P.R.China

01/1997 Frontier of Biomedical Sciences, Los Angeles, CA
02/1997 Keystone Symposium on Hematopoiesis, Tamarrow, CO
10/1997 Institute of Basic Medical Sciences, Beijing, P.R.China
11/1997 Cancer Center, University of Southern California, CA

03/1998 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
03/1998 ThymOs, Heron island, Anstralia
12/1998 American Society of Hematology, Miami, FL

08/1999 2nd Annual Chinese-American Frontiers of Science Symposium (co-sponsored by the U.S. National Academy of Sciences and the Chinese Academy of Sciences), Beijing, P.R.China
08/1999 Biotechnology Workshop (sponsored by the Chinese Academy of Sciences and the Ray Wu Society), Beijing, P.R.China
08/1999 Max-Planck Institute for Immunobiology, Freiburg, Germany
10/1999 The 7th congress of Experimental Hematology, Suzhou, P.R.China

04/2000 The 5th Homeland and Overseas Forum on Life Sciences, Beijing, P.R.China
07/2000 Frontiers of Sciences Symposium, Cap Cord, MA
07/2000 Whitehead Institute for Biomedical Research, MIT, Cambridge, MA
10/2000 Department of Biochemistry, University of California, Riverside, CA
10/2000 Organizer and section chair, the US National Academy of Sciences Committee for American-Chinese Frontier of Sciences, Irvine, CA
11/2000 Special lecture for HHMI-NIH Cloister Scholars, Bethesda, MD
11/2000 NIH, Bethesda, MD
11/2000 Special lecture for HHMI stuff, Chevy Chase, MD
12/2000 Special lectures for Cell Biology, the Chinese Academy of Sciences, Shanghai, P.R. China

04/2001 Society for Chinese Biological Scientists, CA
06/2001 Frontier of Biological sciences in the 21st century, Beijing, P.R.China
07/2001 Beijing Medical University, Beijing, P.R.China
07/2001 PTEN/AKT Summit meeting, Boston, MA
09/2001 Harbor-UCLA medical Center, CA
10/2001 Modeling prostate cancer in mice, Bar Harbor, Main
11/2001 Organizer and speaker, The Peak of Cell Biology, Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, MA

01/2002 Laboratory of Chemical Biology, NIH, Bethesda, MD
01/2002 Somatic and Embryonic Stem Cell Research Symposium, NIH, Bethesda, MD
02/2002 M.D. Anderson Cancer Center, Houston, TX
02/2002 Norris Cancer Center, University of South California, School of Medicine, Los Angeles, CA
03/2002 Department of Chemistry and Biochemistry, University of Colorado-Boulder, CO
04/2002 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
05/2002 The Inaugural Whitehead Institute for Biomedical Research Alumna Symposium, Cambridge, MA
08/2002 The Symposium on the Molecular Basis of Development and Disease, Hunan, P.R.China
08/2002 Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, P.R.China
09/2002 Amgen, Thousand Oaks, CA
10/2002 Academy of Molecular Imaging Annual Conference, San Diego, CA
11/2002 Mouse Model for Human Cancer Consortium-Prostate Cancer SPORE meeting, Bethesda, MD
11/2002 Distinguished Lecture, University of Virginia Medical Scientist Training Program and Cancer Center, Charlottsville, VA
12/2002 The Third Ray Wu Society for Biomedical Research Symposium, San Diego, CA

02/2003 Department of Cell Biology, Harvard Medical School, Boston, MA
03/2003 Research Symposium for Dr. Steve Krane 75th birthday, Harvard Medical School, MA
04/2003 Cancer Center, University of California, San Francisco, CA
04/2003 Department of Biomedical Science, Cornell University, NY
07/2003 AARC 94th Annual Meeting, Symposium on Phosphatase in Cancer, Washington D.C
07/2003 Society for Developmental Biology 62nd Annual meeting, Boston, MA
10/2003 The Prostate Cancer Center, Vancouver, Canada
10/2003 Amgen, Thousand Oaks, CA
10/2003 Department of Cell Biology, Johns Hopkins University, MD
11/2003 American Chinese Medical Association Annual Meeting, Los Angeles, CA
11/2003 Department of Pharmacology, University of Maryland, MD
01/2003 Organizer, The NCI MMHCC symposium on Small Animal Imaging, Los Angeles, CA

01/2004 Organizer and invited speaker, The First International Meeting on PTEN Tumor Suppressor Gene, AZ
02/2004 Cancer Center, University of California, Irvin, CA
03/2004 Derald H. Rutthenberg Cancer Center, Mount Sinai School of Medicine, NY
03/2004 NCI tumor stem cell and self-renewal genes think tank meeting, MD
03/2004 Keynote speaker, The Lymphangioleiomyomatosis Foundation Research Conference, Cincinnati, OH
04/2004 Genentech, CA
05/2004 Therapeutic Targeting of Human Prostate Cancer, Tucson, AZ
06/2004 Merck Research Laboratories, Philadelphia, PEN
06/2004 The Burnham Institute, San Diego, CA
07/2004 The 10th Society of Chinese Bioscientists in America International Symposium, Beijing, P.R.China
09/2004 3rd International Symposium on Developmental Genetics, organized by the Howard Hughes Medical Institute and Fudan-Yale biomedical Center, Shanghai, P.R.China
09/2004 Shanghai Medical School, Fudan University, Shanghai, P.R.China
10/2004 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
10/2004 Prostate Cancer Foundation’s 11th Annual Scientific Retreat, Reno, NV
11/2004 Basic, Translational, and Clinical Advances in the Management of Prostate Cancer, AACR special Conference, Bonita Springs, FL
12/2004 Department of Molecular Cellular and Developmental Biology Annual Scientific Retreat, Lake Arrowhead, CA

02/2005 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
04/2005 The UCLA Stem Cell Symposium, Los Angeles, CA
04/2005 AACR 96th Annual Meeting, Symposium on “Cross-Talk and Signaling Pathways in Tumor Progression and Metastasis”, Anaheim, CA
05/2005 University of Connecticut Health Center, CT
06/2005 Zhejiang University, Hangzhou, P.R.China
07/2005 Invited speaker and section, 2005 Beijing International Symposium on Stem Cell Research, Beijing, China
10/2005 Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA
10/2005 Biomedical Sciences Program, University of California, San Francisco, San Francisco, CA

03/2006 Organizers and speaker, UCLA Symposium on Stem Cell, Pathways, and Cancer: From Biology to Therapy, Los Angeles, CA
03/2006 Wang Ying-Lai Memorial Symposium, The University of Texas Medical Branch, Galveston, TX
04/2006 Stowers Institute for Medical Research and Kansas University Medical College, Kansas city, KA
05/2006 Burnham Institute for Medical Research, San Diego, CA
05/2006 Society of Urologic Oncology, Atlanta, GE
05/2006 Fred Hutchinson Cancer Research Institute, Seattle, WA
06/2006 Institute for Stem Cell Research, Edinburgh, England
06/2006 The Prostate Cancer Research Foundation Symposium, London, England
06/2006 Ludwig Institute for Cancer Research, Brussels, Belgium
07/2006 Section chair and invited speaker, the 11th SCBA International Symposium, San Francisco, CA
09/2006 5th International Symposium on Hormonal Carcinogenesis, Montpellier, France
10/2006 International Conference on Bio-Nano-Informatics Fusion 2006, Beijing, China
10/2006 The Center for Onganogenesis, University of Michigan Medical School, Ann Arbor, Michigan

01/2007 Baylor School of Medicine, Houston, Texas
02/2007 UCLA Symposium on Diabetes and Pancreatic Cancer, Los Angeles, CA
03/2007 Keystone Symposium on “Mouse Models at the Frontiers of Cancer Discovery”, Whistler, British Columbia, Canada
04/2007 Annual convention, Chinese American Engineers and Scientists Association of Southern California, Los Angeles, CA
04/2007 Co-chair, symposium on “Mouse Models of Cancer: Signaling Mechanisms in Initiation, Progression, and Therapeutics”, AACR Annual meeting, Los Angeles, CA
04/2007 Genentech Inc., South San Francisco, CA
04/2007 MSTP Trefethen lecturer, Biomedical Sciences Program, University of California, San Francisco, San Francisco, CA
04/2007 Keynote speaker, University of California, San Francisco MSTP Retreat, San Francisco, CA
05/2007 Symposium on “Stem Cells: Present and Future”, Harvard Medical School, Boston, MA
05/2007 Department of Oncology/Pharmacology, Merck Research Laboratories, Boston, MA
05/2007 Gordon Research Conference on “Cancer Genetics and Epigenetics”, Il Ciocco, Barga, Italy
07/2007 NCI Tumor Microenvironment Steering Committee Meeting, Paolo Alto, CA
07/2007 Organizer, CBIS Sympoisum on Frontier of Biological Sciences, Beijing, China
08/2007 Invited speaker and member of the External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY
10/2007 Cancer Center, Ohio State University, OH
10/2007 Department of Genetics and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
10/2007 Beijing University Medical center, Beijing, China
11/2007 Department of Pathology, Yale School of Medicine, New Heaven, CT
11/2007 Invited speaker and organizer, Xiangshan meeting on “Stem Cell and Cloning”, Beijing, China
12/2007 Key note speaker, California Triple Helix in Regenerative Medicine-6th Annual California tissue engineering meeting, LA, CA

01/2008 Section chair and invited speaker, mTOR Signaling: from Cancer to CNS Function, sponsored by National Institute of Neurological Disorders and Stroke, Bethesda, MD
03/2008 Organizer and section chair: An AACR-ASH joint workshop on PI3-Kinase: A Common Pathway for Hematologic Malignancies and Solid Tumors. Lansdowne, VA
03/2008 Department of Cancer Biology, MD Anderson Cancer Institute, Houston, TX
04/2008 Department of Genetics, Case Western Reserve University, Cleveland, OH
08/2008 SCBA Southern California annual meeting, Los Angeles, CA
09/2008 Medical Scientist Lecture, UC Irvine School of Medicine, Irvine, CA
10/2008 University of Michigan, Ann Arbor, MI
10/2008 Prostate Cancer Foundation, Lake Tahoe, NE
10/2008 Stanford Cancer Center, Stanford University, Palo Alto, CA
10/2008 International Society for Biological Therapy of Cancer, San Diego, CA
11/2008 AACR special conference in “Targeting the PI3-Kinase Pathway in Cancer”, Boston, MA

01/2009 AACR special conference in “Advances in Prostate Cancer Research”, San Diego, CA
01/2009 Intellikine, Inc. La Jolla, CA
03/2009 Memorial Sloan-Kettering Cancer Center, NY
04/2009 International conference on Oncology and Pharmacology, Kunming, P.R.China
04/2009 33rd Annual Scientific Symposium on “Stem Cell and Cancer”, UNC Lineberger Comprehensive Cancer Center, NC
06/2009 Institute of Molecular and cellular Biology, Shanghai, China
06/2009 12th SCBA International Symposium, Taipei, Taiwan
11/2009 Organizer and co-chair, 2009 NCI Translational Medicine Meeting, VA
12/2009 The 2nd Guangzhou International Forum on the Frontier of Stem Cell and Regeneration Biology, Guangzhou, China

02/2010 Cedars-Sinai Medical Center, CA
03/2010 Foundation of IPSEN annual meeting on Stem Cell and Cancer, Bariloche, Argentina
03/2010 Invited speaker and section chair, Cold Spring Harbor meeting on “PTEN Tumor Suppressor”, NY
04/2010 AACR special conference on “Prostate cancer”, Washington DC
04/2010 The Mike Hogg Distinguished Lecture, The University of Texas, MD Anderson Cancer Center, TX
09/2010 NCI animal model clinical trial think tank meeting, Washington DC
12/2010 The 3rd Guangzhou International Forum on the Frontier of Stem Cell and Regeneration Biology, Guangzhou, China

02/2011 Gordon conference on cancer stem cells, Ventura, CA
04/2011 UCSF Cancer Center, San Francisco, CA
04/2011 Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
04/2011 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China
05/2011 University of Southern California, Los Angeles, CA
07/2011 13th SCBA International Symposium, Guangzhou, China
07/2011 Guangzhou Cancer Institute, Guangzhou, China
07/2011 9th CBIS symposium, ZhangjiaJie, China
08/2011 Southern California-Japan Summer Conference, City of Hope, CA
10/2011 Ray Wu Memorial Symposium, Shanghai, China
10/2011 William Laurence and Blanche Hughes Foundation, Cincinnati
11/2011 University of California, Irvine, Irvine, CA
11/2011 42nd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan

04/2012 NCI MMHCC Symposium on Mouse Model of Prostate Cancer, New York City, NY
04/2012 Distinguish Lecture, Texas, A&M University, Houston, TX
05/2012 NCI TMEN Steering Committee, Washington DC
06/2012 The 6th Annual Forum of Prostate Diseases, Shanghai, China
07/2012 From Virus to Epigenetics to Stem Cells, Whitehead Institute, Cambridge, MA
10/2012 William Laurence and Blanche Hughes Foundation, Westlake, CA
10/2012 Prostate Cancer Foundation Annual Meeting, Carlsbad, CA
12/2012 Nankai University, Tianjing, China

01/2013 University of Texas at Southwestern, Dallas, TX
02/2013 MD Anderson Cancer Center, Houston, TX
02/2013 Key Stone Symposium on “PI3-kinase and interplay with other signaling pathways”, Keystone, CO
03/2013 Mount Sinai School of Medicine, New York, NY
04/2013 Stanford University, Paolo Alto, CA
05/2013 Mayo Clinic, Rochester, MN
07/2013 Drs. Tsian Wu and Ray Wu Memorial Symposium, Beijing, China
07/2013 SCBA symposium, Xian, China
09/2013 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress, Amsterdam, Netherland
10/2013 Shanghai International Symposium on Cancer Stem Cells, Shanghai, China
10/2013 William Laurence and Blanche Hughes Foundation, Westlake, CA
10/2013 IMED Seminar, UCLA, Los Angeles, CA
11/2013 Chinese Biochemistry Society, Beijing, China

04/2014 The 3rd Affiliated Hospital, Peking University, Beijing, China
05/2014 Tsinghua University, Beijing, China
06/2014 NCI Tumor Microenvironment meeting, New York
06/2014 The Institute of Cancer Research, London, United Kingdom
06/2014 Bayer Health, Berlin, Germany
07/2014 Sichuan University, Chengdu, China
09/2014 AACR Special Symposium on “Targeting the PI3K/mTOR Pathway”, Philadephia
10/2014 Program committee member and section chair, AACR symposium on “New Horizons in Cancer Research”, Shanghai, China
11/2014 The Inaugural NUS-Peking University Bilateral workshop in Biology, Singapore

03/2015 MIT-TAU-PKU joint symposium, Tel Aviv, Isreal
06/2015 Xiehe Medical University, Beijing, China
07/2015 6th PacRim Breast and Prostate Cancer Symposium, Portland, OR
08/2015 4th Translation Research symposium, Chinese Urological Association, Xiamen, China
09/2015 SPORE Research Symposium, UCLA, USA
09/2015 Peking University – Free University of Berline Joint Symposium, Berlin, Germany
09/2015 Peking University – Bayer Health Sciences Joint Symposium, Berlin, Germany
10/2015 10th International Conference on Genomics, Shenzhen, China
11/2015 Cold Spring Harbor meeting on Cell Death, Suzhou, China
11/2015 Program committee member and speaker, AACR symposium on “New Horizons in Cancer Research”, Shanghai, China

11/2016 Frontier of Cancer Sciences, Singapore

04/2017 Fred Hutchinson Cancer Research Center, Seattle, USA
09/2017 Peking University – Bayer Health Sciences Joint Symposium, Berlin, Germany
09/2017 Cold Spring Harbor meeting on Precision Cancer Biology: From Targeted to Immune Therapies, Suzhou, China
09/2017 First Forum on Frontier of Cancer Research, Peking University, Beijing, China
10/2017 Department of Urology, Johns Hopkins School of Medicine, Baltimore, USA
12/2017 Tsinghua University, “Shui u tsinghua Lecture Series”, Beijing, China

04/2018 UK-China conference on Inflammation and Cancer, Beijing, China
07/2018 Gordon Research Conference on “Personalized Medicine”, Hong Kong
08/2018 School of Life Sciences, University of Macau, Macau
11/2018 The 3rd International Conference on Cancer Translational Research, Tianjin, China
11/2018 Whitehead Institute for Biomedical Research, MIT, Cambridge, MA USA

03/2019 Novartis R&D Global Advisory Meeting, Shanghai, China
05/2019 Co-chair of the program committee, AACR symposium on “New Horizons in Cancer Research”, Shenzhen, China

06/2021 2021 Ray Wu prize award ceremony and symposium, Shanghai, China
09/2021 The 1st PKU-Janssen innovative research symposium, Beijing, China
10/2021 PKU-Oxford symposium on cancer epigenetics (online)
12/2021 PKU-Tsinghua-BI webinar on immune cell dynamics and diseases (online)

03/2022 Worldwide PI3K Zoom Seminar (online)
03/2022 University of Hong Kong, Hong Kong, China (online)
10/2022 JnJ Research Seminar (online)

02/2023 LSCCB, Science Park, Hong Kong, China
05/2023 University of Chicago, Chicago, USA
10/2023 “Cancer Research Symposium”, Shenzhen, China
11/2023 PKU-Tsinghua-Bayer Research Symposium, Wuppertal, Germany

06/2024 UMass Chan Medical School, Worcester, USA
07/2024 The 19th SCBA/14th CBIS Biennial Symposium, Guiyang, China
11/2024 Xplorer Symposium on Chemical Decoding of Spatial Biology, Shenzhen, China

PTEN is the second most frequently deleted tumor suppressor gene in human cancers. PTEN mutation also was found to be the cause of three autosomal dominant tumor predisposition syndromes. A major focus of Dr. Hong Wu's research is to study the molecular mechanism of PTEN controlled tumorigenesis. For this, she has undertaken a combination of molecular genetics, cell biology and biochemical approaches. By analyzing cells and animals lacking the PTEN tumor suppressor, Wu and her colleagues have demonstrated that PTEN negatively regulates stem cell self-renewal, proliferation and survival. Thus, their study provides a strong link between stem cell biology and cancer biology and suggests that tumors may originate through the transformation of stem cells. They also established various animal models for human cancers, including T-ALL and prostate cancer models. These murine cancer models offer unique tools for both exploring the molecular mechanism underlying human cancers and for the development of new therapies.

1. Wang, X., Zhang, L.,Guo, F., Yao N., Wu Z., He L., Xu D., Zhu H., Gong Z., Xie W., Wang Y., Zhang L., Zhou X., Tang C., Mu R., Wu H* and Lei X. (2025) Small-molecule inhibitors of transcription factor PU.1 for the treatment of acute T cell lymphoblastic leukemia and organ fibrosis. CCS Chemistry (in press).
2. Chen T, Xie S, Cheng J, Zhao Q, Wu H*, Jiang P*, Du W*. (2024) AKT1 phosphorylation of cytoplasmic ME2 induces a metabolic switch to glycolysis for tumorigenesis. Nat Commun. Jan 23;15(1):686.
3. Xu Z., He L., Wu Y., Yang L., Li C.and Wu H. (2023) PTEN regulates hematopoietic lineage plasticity via PU.1-dependent chromatin accessibility. Cell Rep. 42(8):112967.
4. Qi Y., Ding L., Zhang S., Yao S., Ong J., Li Y., Wu H. and Du P (2022) A plant immune protein enobles broad antitumor response by rescuing microRNA deficiency. Cell, 185: 1888-1904.
5. Qi Z., Xu Z., Zhang L., Zou Y., Li J., Yan W., Li C., Liu N. and Wu H. (2022) Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3K treatment. Nature Commun PMID:35013322.
6. Xue Y., Yang Y., Tian T., Quan, H., Liu S., Zhang L., Yang L., Zhu H., Wu H. and Gao Y. (2022). Computational characterization of domain-segregated 3D chromatin structure and segmented DNA methylation status in carcinogenesis. Mol Oncol. 16:699-716.
7. Zhu H., Dong B., Zhang Y., Wang M., Wang J., Cui B., Liu Y., Jiang Q., Wang W., Yang L., Yu A., Li Z., Liu C., Zhang L., Huang X., Zhu X. and Wu, H. (2022) Integrated genome analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. Blood Sci. 4:16-28.
8. Yang L., Chen F., Zhu H., Chen Y., Dong, B., Shi M., Wang W., Jing Q., Zhang L., Huang, X., Zhang, Q. and Wu, H. (2021) 3D genome alterations associated with dysregulated HOXA13 expression in high-risk T-lineage acute lymphoblastic leukemia. Nature Commun. PMID:34140506.
9. Cheng J., Huang Y, Zhang X., Yu Y., Wu S., Jiao J., Tran L., Zhang W., Liu R., Zhang L., Wang MY., Wang M., Yan W., Wu Y., Chi F., Jiang P., Zhang X. and Wu H. (2020) TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nature Commun. 1191):1880 PMID:32312982.
10. Wu YL., Zhu HC. and Wu H. (2020) PTEN in regulating hematopoiesis and leukenogenesis. Cold Spring Harb Perspect Med. 10:a036244.
11. Zhu HC., Zhang LZ., Wu YL., Dong B., Guo W., Wang M., Yang L., Fan X., Tang Y., Liu NS., Lei X. and Wu H. (2018) T-ALL leukemia stem cell “stemness” is epigenetically controlled by the master regulator SPI1. Elife 7:eLife38314 PMID:30412053 (Free PMC article)
12. Zou YK., Qi, Z., Guo, WL., Zhang, LZ., Ruscetti, M., Shenoy, T., Liu NS. and Wu, H. (2018) Cotargeting the cell-intrinsic and microenvironment pathways of prostate cancer by PI3Ka/b/d inhibitor BAY1082439. Molecular Cancer Therapeutics 17:2091-2099 (Highlighted by Mol. Cancer Thera 2018).
13. Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H. (2017) CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. 28:1495-1507(Highlighted by Ann Oncol 2017)
14. Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG (2017) Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 13:914 PMID:28202506
15. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. (2016) PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med 22:379087. PMID: 26974310
16. Guo, W.L., Zhang, M. and Wu, H. (2016) Mammalian non-CG methylations are conserved and cell-type specific and may have been involved in the evolution of transposon elements. Sci Rep 6.32207 PMCID:PMC5004121

17. Schubbert S., Jiao, J., Ruscetti, M., Nakashima, J., Wu, S., Lei, H., Xu, Q., Yi, W., Zhu, H., Wu, H. (2015) Methods for PTEN in Stem Cells and Cancer Stem Cells. In PTEN: Methods and Protocols (ed. L. Salmena and V. Stambolic), pp233-285. Springer New York Heidelberg Dordrecht London. PMID:27033080
18. Ruscetti, M., Dadashian, E.L., Guo, W., Quach, B., Mulholland D.J., Park J.W., Tran, L.M., Kobayashi, N., Bianchi-Frias, D., Nelson, P.S., Xing, Y. and Wu, H. (2015) HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer. Oncogene 35(29):3781-95 PMID:26640144

19. Shnitsar, I., Bashkurov, M., Masson, G.R., Ogunjimi, A.A., Mosessian, S., Cabeza, E.A., Hirsch, C.L., Trcka, D., Gish, G., Jiao, J., Wu, H., Winklbauer, R., Williams, R.L., Pelletier, L., Wrana, J.L. and Barrios-Rodiles, M. (2015) PTEN regulates cilia through Dishevelled. Nat Commun. 6:8388. PMID: 26399523
20. Bianchi-Frias, D.,Hernandez, S.A.,Coleman, R., Wu, H., Nelson, P.S.(2015) The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma. Mol Cancer Res. 13(2):339-47. PMID: 25298407
21. Ruscetti, M., Quach, B., Dadashian, E.L., Mulholland, D.J. and Wu, H. (2015) Tracking and functional characterization of EMT and mesenchymal-like tumor cells in prostate cancer metastasis. Cancer Res. 75:2749-59. PMCID:PMC4490048.
22. Lazovic J, Guo L, Nakashima J, Mirsadraei L, Yong W, Kim HJ, Ellingson B,Wu H, Pope WB. (2015) Nitroxoline Induces Apoptosis ans Slows Glioma Growth in vivo. Neuro Oncol. 17：53-62 PMID:25074541
23. Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner JE, Wu H. Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T cell acute lymphoblastic leukemia. (2014) Cancer Res 74：7048-59. PMCID:PMC4258248
24. Shurell, E., Tran, L.M., Nakashima, J., Smith, K.B., Tam, B.M., Li, Y., Dry, S.M., Federman, N., Tap, W., Wu H*., Eilber,F.C. (2014) Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer 14:827 PMCID:PMC4237782
25. Hsia HE, Kumar R, Luca R, Takeda M, Courchet J, Nakashima J, Wu S, Goebbels S, An W, Eickholt BJ, Polleux F, Rotin D, Wu H, Rossner MJ, Bagni C, Rhee JS, Brose N, Kawabe H. (2014) Ubiquitin E3 Ligase Nedd4-1 Acts as a Downstream Target of PI3K/PTEN-mTORC1 Signaling to Promote Neurite growth. Proc Natl Acad Sci USA 111:13205-10. PMCID:PMC4246980
26. Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR. (2014) A Uniform Nomenclature and Amino Acid Numbering for Human PTEN. Science Signal. 7: pe15 PMCID:PMC4367864
27. Garcia, A.J., Ruscetti, M., Arenzana, T.L., Tran, L.M., Frias D.B., Sybert, E., Priceman, S.J., Wu, L., Nelson, P., Smale, S and Wu, H. (2014) Pten null prostate epithelium promotes localized MDSC expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 34:2017-2028. PMCID:PMC4019050
28. Tesio, M., Oser, G., Baccelli, I., Blanco-Bose, W., Wu, H., Gothert, J., Kogan, S. and Trumpp, A. (2014) Pten Loss in the Bone Marrow Leads to G-CSF-Medicated HSC Mobilization. J. Exp. Medicine 210:2337-2349. PMCID:PMC3804947
29. Wang, L., Teng, R., Di, L., Roger, H., Wu, H., Kopp, J.B., and Noguchi, C.T. (2013) PPARa and Sirt1 Mediate Erythopoietin Action in Increasing Metabolic Activity and Browning of White Adipocytes to Protect Against obesity and Metabolic Disorders. Diabetes 62:4122-31.PMCID: PMC3837041
30. Ruscetti, M. and Wu, H. (2013) PTEN in Prostate Cancer. In Prostate Cancer: Biochemistry, Molecular Biology, Genetics. (ed. D. J. Tindall), pp87-137. Springer New York Heidelberg Dordrecht London
31. Mulholland, D. and Wu, H. (2013) Genetic and Signaling Pathway Regulations of Tumor-initiating Cells of the Prostate. In Stem Cells and Prostate Cancer (ed. S.D. Cramer), pp77-89. Springer New York Heidelberg Dordrecht London
32. Farrell, J., Toste, P., Wu, N., Li, L.,Wong, J., Malkhassian, D., Tran, L., Wu, X., Li X., Dawson, D., Wu, H. and Donahue, T. (2013) Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 are Associated with Invasive Cancer. American Journal of Gastroenterology 108(8) 1352-1359.
33. Smith, K.B., Tran, L.M., Tam, B., Shurell, E.M., Li, Y., Braas, D., Tap, W.D., Christofk, H.R., Dry, S.M., Eiber, F.C., and Wu, H. (2013) Novel dedifferentiated liposarcoma xenograft models reveal PTEN down regulation as a malignant Signature and Response to PI3K Pathway Inhibition American Journal of Pathology 182(4):1400-11. PMCID: PMC3620414.
34. Braas, D., Ahler, E., Tam, B., Nathanson, D., Riedinger, M., Benz, M.R., Smith, K.B., Eilber, F.C., Witte, O.N., Tap, W.D., Wu, H. and Christofk, H.R (2012) Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment. Cancer Discovery 2(12):1109-1117. PMCID: PMC3531869.
35. Kim, T.H., Song, J., Alcantara Liaguno, S.R., Murnan, E., Liyanarachchi, S., Palanichamy, K., Yi, J.Y., Viapiano, M.S., Nakano, I., Yoon, S.O., Wu, H., Parada, L.F., and Kwon, C.H. (2012) Suppression of Peroxiredoxin 4 in Glioblastoma Cells Increases Apoptosis and Reduces Tumor Growth. PLoS One 7(8): e42818. PMCID: PMC3419743.
36. Di Vizio, D., Morello, M., Dudley, A., Chow, P., Adam, R., Morley, S., Mulholland, D., Rotinen, M., Hager, M., Insabato, L., Moses, M., Demichelis, F., Lisanti, M., Wu, H., Klagsbrun, M., Bhowmick, N., Rubin, M., D’Souzas, C., and Freeman, M. (2012) Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. Am J Pathol. 181(5): 1573-84. PMCID: PMC3483805.

37. Jiao, J., Hindoyan, A., Wang, S., Tran, L., Goldstein, A., Lawson, D., Chen, D., Li, Y., Guo, C, Zhang, B., Fazli, L., Gleave, M., Witte, O., Garraway, I. , and Wu, H. (2012) Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS One 7(8):e42564. PMCID: PMC34117.
38. Schlacher, K., Wu, H., and Jasin, M. (2012) A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2. Cancer Cell 22(1):106-16. PMID: 22789542
39. Hill, R., Li, Y., Tran, L.M., Dry, S., Calvopina, J.H., Garcia, A., Kim, C., Wang, Y., Donahue, T.R., Herschman, H.R., and Wu, H. (2012) Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development. Mol Cancer Ther. 11(10):2127-37. PMCID: PMC3469770
40. Graham, N., Tahmasian, M., Kohli, B., Komisopoulou, E., Zhu, M., Vivanco, I., Teitell, M., Wu, H., Ribas, A., Lo, R., Mellinghoff, I., Mischel, P., and Graeber, T.G.(2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death Mol Syst Biol. 8(1): 589. PMCID: PMC3397414
41. Hubner, A., Mulholland, D., Standen, C., Karasarides, M., Cavanagh-Kyros, J., Barrett, T., Chi, H., Greiner, D., Tournier, C., Flavell, R., Sawyers, C., Wu H., and Davis, R. (2012) JNK and PTEN co-operatively control the development of invasive adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. USA 109(30):12046-51. PMCID: PMC3409732
42. Mulholland, D., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L.M., Huang, J., Gleave, M and Wu, H (2012) Pten loss and RAS/MAPK activation coorperate to promote EMT and prostate cancer metastasis initiated from stem/progenitor cells. Cancer Res. 72 (7):1878-89. PMCID: PMC3319847
43. Tran, L.M., Chang, C., Plaisier, S., Dang, J., Mischel, P.S., Liao, J., Graeber, T.G. and Wu, H. (2012) Determining PTEN functional status by network component deducted transcription factor activities. PLoS One 7(2):e31053. PMCID: PMC 3275574
44. Donahue, T.R., Tran, M.L., Hill, R., Li, Y, Kovochich, A., Calvopina, J., Patel, S.G., Farrell, J.J., Li, X., Dawson, D. and Wu, H. (2012) Integrative survival-based molecular profiling of Human Pancreatic Cancer. Clinic Cancer Res. 18(5): 1352-63. PMID: 22261810
45. Moon BC, Hernandez-Ono A, Stiles B, Wu H, Ginsberg HN. Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Artherioscler Thromb Vasc Biol. 2012 Feb;32(2):236-46
46. Pope, W.B., Prins, R.M., Thomas, A., Nagarajan, R., Yen, K., Bittinger, M.A., Salamon, N., Choud, A.P., Yong, W.H., Soto, H., Wilson, N., Driggers, E., Jang, H.G., Su, S.M., Schenkein, D.P., Lai, A., Cloughey, T.F., Kornblum H.I., Wu, H., Fantin, V.R., Liau, L.M. (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 107(1):197-205. PMCID: PMC3650613.
47. Valamehr, B., Tsutsui, H., Ho, C.M., and Wu, H (2011) Developing defined culture system for human pluripotent stem cells. Regen. Med. 6:623-634. PMID: 21916597
48. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu, H., Song M, Dorigo O. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clinic Cancer Res. 17:2373-84. PMCID: PMC3078990

49. Palaskas NJ, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber E, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu, H., Sander C, Phelps ME, Brennan CW, Port E, Huse JT, Graeber TG, Mellinghoff I.(2011) 18F-fluorodeoxy-glucose positron emission tomography (18FDG-PET) marks MYC-overexpressing human basal-like breast cancers. Cancer Res 71:5164-74. PMCID: PMC3148325
50. McCabe K. E, Liu B, Marks J.D, Tomlinson J.S, Wu, H., Wu A. (2011) An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors. Molecular Imaging & Biology. 111(6). PMCID: PMC3227780
51. Mulholland, D., Tran, M.L., Cai, H., Morim, A., Wang, S., Plaisier, S., Huang, J., Garraway, I., Graeber, T. and Wu, H. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792-804. PMCID: PMC3157296.
52. Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H. and Jasin, M. (2011) Homologous recombination independent role for BRCA1 in blocking stalled replication folk degradation by MRE11. Cell 145, 529-542. PMCID: PMC3261725
53. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Klemm L, Nahar R, Park E, Kim YM, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A and Müschen M. (2011) BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition. Nature 473:384-8. PMCID: PMC3597744
54. Lindgren, A.G., Natsuhara, K., Tian, E., Vincent, J.J., Li X., Jiao, J., Wu, H., Banerjee, U. and Clark, A.T. (2011) Loss of Pten causes tumor initiation following differentiation of murine pluripotent stem cells due to failed repression of Nanog. PLoS One. 6(1):e16478. PMCID: PMC3029365
55. Le Belle, J., Orozco, N.M., Paucar, A., Saxe, J., Mottahedeh, J., Pyle, A., Wu, H. and Kornblum, H. (2011) Proliferative neural stem cell maintain high endogenous levels of reactive oxygen species that regulate self-renewal and neurogenesis in a PI3K/AKT-dependent manner. Cell Stem Cell 8 (1): 59-71. PMCID: PMC3018289
56. Guo, W., Schubbert, S., Chen, J-Y, Valamehr, V., Mosessian, S., Shi, H., Garcia, C., Theodoro, M.F., Varella-Garcia, M and Wu, H. (2011) Suppression of leukemia and leukemia stem cell transformation. Proc. Natl. Acad. Sci. USA 108, 1409-14. PMCID: PMC3029702
57. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, and Anderson L. (2011) Evaluation of well differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 50(2):95-112. PMID:21117066
58. Lukacs, R., Memarzadeh, S., Wu, H. and Witte, O (2011) Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6):682-93. PMCID: PMC3019762
59. Tsutsui, H., Valamehr, B., Hindoyan, A., Qiao, R., Ding, X., Guo, S., Witte, O., Liu, X., Ho, C.M., and Wu, H. (2011) An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nature Communications 2:167. PMCID: PMC3161511
60. Choi, D., Schroer, S., Lu, S., Wang, L., Wu, X., Liu, Y., Zhang, Y., Gaisano, H., Wagner, K., Wu, H., Retnakaran, R., Woo, M. (2010) Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J. Exp. Med. 207, 2831-2842. PMCID: PMC3005231
61. Hill, R., Calvopina, J.H., Kim, C., Wang, Y., Dawson, D.W., Donahue, T.R., Dry, S., Wu, H. (2010) PTEN Loss Accelerates KrasG12D-Induced Pancreatic Cancer Development. Cancer Res 70 (18):7114-24. PMCID: PMC2940963
62. Tsutsui, H., Yu, E., Marquina, S., Valamehr, B., Wong, I., Wu, H. and Ho, C-M (2010) Efficient dielectrophoretic patterning of embryonic stem cells in energy landscapes defined by hydrogel geometries. Ann. Biomed. Eng. PMCID: PMC2975918
63. Sun, J., Materman-Smith, M., Graham, N., Jiao, J., Mottahedeh, J., Laks, D., Ohashi, M., DeJesus, J., Kamei, K., Lee, K., Wang, H., Yu, S., Lu, Y., Hou, S., Li K., Liu, M., Zhang, N., Wang, S., Angenieux, B., Panosyan, E., Samuel, E., Park, J., Williams, D., Konkankit, V., Mathanson, D., van Dam, R.M., Phelps, M., Wu, H., Liau, L., Mischel, P., Lazareff, J., Kornblum, H., Yong, W., Graeber, T.G., Tseng, H.R. (2010) A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res. 70:6128-38. PMCID: PMC3163840
64. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. (2010) The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. USA 107:6459-64. PMCID: PMC2851999
65. Mosessian, S and Wu, H. (2010) PTEN-Associated Complex: An Overview. Curr. Topic. Biochem. Res. 12:37-42. PMCID: PMC3212753
66. Lillehoj, P.B., Tsutsui, H., Valamehr, B., Wu, H. and Ho, C-M (2010) Continuous sorting of heterogenous-sized embryoid bodies. Lab on a Chip 10:1678-82. NIHMS317101
67. He, L., Hou, X., Kanel, G., Wang, Y., Yang, J., Wu, H., Birnbaum, M. and Stiles, B (2010) The Critical Role of AKT2 in Hepatic Steatosis Induced by PTEN Loss. American J. Path 176:2302-8. PMCID: PMC2861095
68. Wang, S., Wang, H., Jiao, J., Chen, K-J., Owens, G.E., Kamei, K-I., Sun, J., Sherman, D.J., Behrenbruch, C.P., Wu, H. and Tseng H-R. (2009) Three-Dimensional Nanostructured Substrates Toward Efficient Capture of Circulating Tumor Cells. Angew.Chem. Int. Ed 48:8970-8973. PMCID: PMC2878179
69. Gregorian, G., Nakashima, J., Dry, S.M., Nghiemphu, P.L., Smith, K.B., Ao, Y., Dang, J., Lawson, G., Mellinghoff, I.K., Mischel, P.S., Phelps, M., Parada, L., Liu, X., Sofroniew, M.V., Eilber, F.C. and Wu, H. (2009) PTEN Dosage is Essential for Neurofibroma Development and Malignant Transformation. Proc. Natl. Acad. Sci. USA 106: 19479-84. PMCID: PMC2765459
70. Mosessian, S., Avliyakulov, N.K., Mulholland, D.J., Boontheung, P., Loo, J.A. and Wu, H. (2009) Analysis of PTEN Complex Assembly and Identification of Heterogeneous Nuclear Ribonucleoprotein C as a Component of the PTEN-associated Complex. J. Biol. Chem 284: 30159-66. PMCID: PMC2781571
71. Mulholland, D.J., Xin, L., Morim, A., Lawson, D., Witte, O., and Wu, H (2009) Lin-Sca-1+CD49high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69:8555-8562. PMCID: PMC2783355
72. Couto, S., Cao, M., Duarte, P., Banach-Petrosky, W., Wang, S., Romanienko, P., Wu, H., Cardiff, C., Abate-Shen, C. and Cunha, G. (2009) Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 77: 103-111. PMCID: PMC2828345
73. Guertin, D.A., Stevens, D.M., Saitoh, M., Crosby, K., Cormier, K.S., Mulholland, D.J., Magnuson, M.A., Wu, H., Sabatini, D.M. (2009) The mTOR complex 2 is required for the development of prostate cancer induced by PTEN loss in mice. Cancer Cell 15:148-59. PMCID: PMC2701381
74. Gregorian, C., Nakashima, J., Ohab, J., Kim, R., Liu, A., Groszer, M., Garcia, D., Sofroniew, M., Carmichael, T., Liu, X. and Wu, H. (2009) Pten Deletion in Adult Neural Stem/Progenitor Cells Enhances Constitutive Neurogenesis. J. Neuroscience 29: 1874-86. PMCID: PMC2754186
75. Conway, A., Lindgree, A., Galic, Z., Pyle, A., Wu, H., Zack, J., Pelligrini, M., Teitell, M., Clark, A. (2009) A pluripotency and self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell derived tumors. Stem cell 27:18-28.PMCID: PMC3194037
76. Ruan, R., Ren, S., Li, J., Li, G., Kim, R., Gao, J., Wu, H., Wang Y. (2009) Inducible and Cardiac Specific PTEN Inactivation Protects Ischemia/Reperfusion Injury, Journal of Molecular and Cellular Cardiology 46:193-200. PMID: 19038262
77. Haga, K., Tomioka, A., Liao, C., Kimura, T., Matsumoto, H., Ohno, I., Hermann, K., Logg, C., Tanaka, M., Hirao, Y., Wu, H., Kruse, C., Roy-Burman, P., and Kasahara N. (2009) PTEN knockout prostate cancer as a model for experimental immunotherapy. J. Urol. 181:354-62. PMCID: PMC2838731
78. Hill, R and Wu, H. (2008) PTEN, stem cells, and cancer stem cells. J. Biol. Chem. 284:11755-11759. PMCID: PMC2673242
79. Valamehr, B., Jonas, S., Polleux, J., Kam, K, Qiao, R., Stiles, B., Luo, T., Witte, O., Liu, X., Dunn, B. and Wu, H. (2008) Hydrophobic Surfaces for Enhanced Differentiation of Embryonic Stem Cells. Proc. Natl. Acad. Sci. USA 105:14459-64. PMCID: PMC2567159
80. Majumder, P., Grisanzio, C., O’Connell, F., Barry, M., Brito, J., Xu, Q., Guney, I., Berger, R., Herman, P., Bikoff, R., Fedele, G., Baek, W., Wang, S., Ellwood-Yen, K., Wu, H., Sawyers, C., Signoretti, S., Hahn, W., Loda, M., Sellers, W. (2008) A prostatic intraepithelial neoplasia-dependent p27kip1 checkpoint induces senescence, inhibits cell proliferation and cancer progression. Cancer Cell 14: 146-55. PMCID: PMC2583442
81. Degtyarev, M., De Mazière, A., Orr, C., Lin, J., Tien, J., Prior, W., Lee, B., van Dijk, S., Gray, D., Wu, H., Davis, D., Stern, H., Murray, L., Hoeflich, K., Klumperman, J., Friedman, L. and Lin, K. (2008) Akt Inhibition Promotes Autophagy And Sensitizes PTEN-Null Tumors To Late-Stage Autophagy Inhibition. J. Cell Biol. 183:101-6. PMCID: PMC2557046
82. Burton JB, Johnson M, Sato M, Koh SB, Stout S, Mulholland D, Chatziioannou AF, Phelps M, Wu H. and Wu L. (2008) Adenovirus Mediated Gene Expression Imaging to Directly Detect Sentinel Lymph Node Metastasis of Prostate Cancer. Nature Med. 14:882-9. PMCID: PMC2811163
83. Yao, D., Alexander, C., Quinn, J., Chan, W., Wu, H. and Greenhalgh, D. (2008) Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma due to p53/p21WAF-induced differentiation triggered by GSK3 inactivation and reduced AKT activity. J. Cell Science 121:1758-69. PMID: 18445683
84. Kwon, C.H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D., Mason, R.P., Lee, E.Y-H., Wu, H and Parada, L. (2008) Pten haploinsufficiency accelerates formation of high grade astrocytomas. Cancer Res. 68:3286-94. PMCID: PMC2760841
85. Mulholland, D.J., Jiao, J. and Wu, H (2008) Hormone refractory prostate cancer: lesions leaned from the PTEN prostate cancer model. Adv Exp Med Biol 617:87-95. PMID:18497033
86. Chang, C., Mulholland, D., Valamehr, B., Mosessian, S., Sellers, W. and Wu, H. (2008) PTEN Nuclear Localization Is Regulated by Oxidative Stress and Responsible for p53-Dependent Tumor Suppression. Mol. Cell. Biol. 28:3281-9. PMCID: PMC2423144
87. Guo, W., Lasky, J, Chang, C., Mosessian, S., Lewis, X., Xiao, Y., Yeh, J., Chen, J., Iruela-Arispe, L., Varella-Garcia, M. and Wu, H. (2008) Multi-genetic events collaboratively to Pten-null leukaemia stem-cell formation. Nature 453: 529-533. PMCID: PMC2840044
88. Iwanaga, K., Yang, Y., Raso, M., Ma, L., Hanna, A., Thilaganathan N., Moghaddam, S., Evans, C., Li, H., Cai, W., Sato, M., Minna, H., Wu, H., Creighton, C., Demayo, F., Wistuba, I. and Kurie, J. (2008) Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 68: 1119-1127. PMCID: PMC2750029
89. Memarzadeh, S., Xin, L., Mulholland, D., Mansukhani, A., Wu, H., Teitell, M., and Witte, O. (2007) Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen Receptor. Cancer Cell 12: 572-585. PMCID: PMC2931420
90. Tahk S., Liu, B., Chenishof, V., Wong, K., Wu, H. and Shuai, K (2007) Control of specificity and magnitude of NF-kB and STAT1-mediated gene activation through PIASy and PIAS1 co-operation. Proc. Natl. Acad. Sci. USA 104: 11643-11648. PMCID: PMC1913887
91. Berquin, I.M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J.M., Thomas, M.J., Thornburg, T., Kulik. G., Smith, A., Edward, I.J., D’Agostino, R., Zhang, H., Wu, H., Kang, J.X., Chen, Y.Q (2007) Modulation of Prostate Cancer Genetic Risk by Omega-3 and Omega-6 Fatty Acids. J. Clinic. Inv. 117:1966-1975. PMCID: PMC1890998
92. Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P., Sawyers, C. and Wu, H. (2007) Murine Cell Lines Derived from Pten Null Prostate Cancer Demonstrate the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research 67: 6083-91. PMID: 17616663
93. Vivanco, I., Palaskas, N., Tran, C., Finn, S.P., Getz, G., Kennedy, N.G., Jiao, J., Rose, J., Xie, W., Loda, M., Golub, T., Mellinghoff, I., Davis, R., Wu, H. and Sawyers, C.L (2007) Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell 11: 555-569. PMID:17560336
94. He, X., Zhang, J., Grindley, J.C., Tian, Q., Sato, T., Tao, W.A., Dirisina, R., Porter-Westpfahl, K.S., Hembree, M., Johnson, T., Wiedemann, L., Barrett, T., Hood, L., Wu, H. and Li, L. (2007) Inactivation of PTEN leads to enhanced activation of intestinal stem cells and biasing on lineage fate determination. Nature Genetics 39: 189-98. PMID: 17237784
95. Shen, W. H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, PP, and Yin, Y. (2007) Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity. Cell, 128:157-70. PMID: 17218262
96. Horvath S, Lu KV, Zhang B, Carlson M, Lu KV, Fang Z, Zhu S, Felciano RM, Laurance MF, Freije W, Castro-Vargas FE, Scheck AC, Liau LM, Wu H, Kornblum HI, Geschwind DH, Cloughesy TF, Nelson SF, Mischel PS (2006) A Module-Based Analysis Identifies ASPM as a Novel Glioblastoma Target. Proc. Natl. Acad. Sci. USA 103: 17402-7. PMCID: PMC1635024
97. Huang, W., Chang, H.Y., Wu, H. and Chen, Y-G (2006) GSK3b mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26: 2471-2482. PMID:17043650
98. Freeman, D., Lesche, R., Kertesz, N., Wang, S-Y., Li, G., Gao, J., Groszer, M., Martinez-Diaz, H., Rozengurt, N., Thomas, G., Liu, X., and Wu, H. (2006) Genetic Background Controls Tumor Development in Pten Deficient Mice. Cancer Research 66: 6492-6496. PMID:16818619
99. Xu, X-L., Kobayashi, S., Qiao, W-H., Li, C-L., Xiao, C-Y., Radaeva, S., Stiles, B., Wang, R-H., Ohara, N., Yoshino, T., LeRoith, D., Torbenson, M.S., Gores, G.J., Wu, H., Gao, B., Deng C-X. (2006) Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J. Clinic. In. 116:1843-1852. PMCID: PMC1474816
100. Zhang, J., Grindley, J., Yin, T., Jayainghe, S., He, X., Ross, J., Haug, J., Rupp, D., Porter-Westpfahl, K., Wiedemann, L., Wu, H., and Li, L (2006) An essential role of PTEN in hematopoietic stem cell maintenance, lineage choice, and leukemia prevention. Nature 441: 518-522. PMID: 16633340
101. Lei, Q., Jiao, J., Xin, L., Chang, C., Wang, S., Gao, J., Gleave, M.E., Witte, O., Liu, X. and Wu, H. (2006) NKX3.1 stabilizes p53, inhibits AKT activation and delays prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367-78. PMID:16697957
102. Yilmaz, O.H., Valdez, R., Threisen, B.K., Guo, W., Ferguson, D.,O., Wu, H., Morrison, S.J. (2006) Pten dependence distinguishes hematopoietic stem cells from leukemia initiating cells. Nature 441: 475-482. PMID:16598206
103. Li, G., Hu, Y., Liu, M., Huo, Y., Freeman, D., Gao, J., Liu, X., Wu, D-C., Wu, H. (2006) PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin J. Biol. Chem. 281:10663-10668. PMID:16507572
104. Guo, W, Lasky, J. and Wu, H. (2006) Cancer stem cells Pediatr Res. 59: 59R-64R.
105. Stiles, B., Kurlawalla-Martinez, C., Guo, W., Gregorian, C., Wang, Y., Tian, J. Magnuson, M.A. and Wu, H. (2006) Selective deletion of Pten in pancreatic -cells leads to increased  cell mass and resistance to STZ-induced diabetes. Mol. Cell Biol. 26:2772-81. PMCID: PMC1430339
106. Khodavirdi, A., Song, Z., Yang, S., Wang, S., Wu, H., Pritchard, C., Nelson, P., Roy-Burman, P. (2006) Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Research 66: 883-888. PMID:16424021
107. Yoo, L.I., Liu, D.W., Vu, S.L., Bronson, R.T., Wu, H. and Yuan, J. (2006) Pten Deficiency Activates Distinct Downstream Signaling Pathways in a Tissue Specific Manner. Cancer Research 66(4):1929-39. PMID:16488991
108. Yao, D., Alexander, C. L., Quinn, J. A., Porter, M. J., Wu H. and Greenhalgh, D.A. (2006) PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation, but malignant conversion proceeds via PTEN-associated pathways. Cancer Research 66(3):1302-12. PMID:16452183
109. Mulholland, D.J., Dedhar, S., Wu, H. and Nelson, C. C (2006) PTEN & GSK3β: key regulators of progression to androgen independent prostate cancer. Oncogene 25(3):329-37.
110. Tsai, P., Ohab, J., Kertesz, N., Groszer, M., Matter C, Gao, J., Liu, X., Wu, H. and Carmichael, S.T. (2006) A Critical Role of Erythropoietin Receptor in Neurogenesis and post-stroke recovery. J. Neurosciences 26:126901274. PMID:16436614
111. Wang, S., Garcia, A., Wu, M., Lawson, D., Witte, O. and Wu, H. (2006) Pten deletion leads to the expansion of prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA 103:1480-1485. PMCID: PMC1345717
112. Groszer, M., Erickson, R., Scripture-Adams, D., Dougherty, J., LeBelle, J., Zack, J., Geschwind, D., Liu, X., Kornblum, H. and Wu, H. (2006) PTEN Negatively Regulates Neural Stem Cell Self-Renewal by Modulating G0-G1 Cell Cycle Entry. Proc. Natl. Acad. Sci. USA 103:111-116. PMCID: PMC1325011
113. Berquin, I., Min, Y., Wu, R., Wu, H and Chen, Y.Q. (2006) Expression signature of the mouse prostate. J. Biol. Chem 280:36442-51.
114. Stanger, B.Z., Stiles, B., Lauwers, G., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K., McLaughlin, P., Brown, D., DePinho, R., Wu, H., Melton D. and Dor Y. (2005) Supplemental data Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8:185-172. PMID:16169464
115. Nakano, I., Paucar, A.A., Bajpai, R., Dougherty, J,.D., Zewail, A., Kelly, T.K., Kim, K.J., Ou, J., Groszer, M., Imura, T., Freije W.A., Nelson, S.F., Sofroniew, M.V., Wu, H., Liu, X., Terskikh, A.V., Geschwind, D.H., and Kornblum, H.I. (2005) Maternal Embryonic Leucine Zipper Kinase (MELK) Regulates Multipotent Neural Progenitor Proliferation. J. Cell Biol. 170:413-427. PMCID: PMC2171475
116. Yue, Q., Groszer, M., Gil, J.S., Berk, A.J., Messing, A., Wu, H., Liu, X. (2005) PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132:3151-3326.PMID:15944184
117. Shi, Y., Sharma, A., Wu, H., Lichtenstein, A. and Gera, J. (2005) Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J. Biol. Chem. 280:10964-73. PMID:15634685
118. Sanchez, T., Thangada, S., Wu, M.T., Kontos, C., Wu, D., Wu, H. And Hla T. (2005) PTEN as an effector in the signaling of anti-migratory G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 102:4312-7. PMCID: PMC555509
119. Lasky, J. and Wu, H. (2005) Notch signaling, brain development and human disease. Pediatr Res. 57:104R-109R.
120. Liu, B., Yang, R., Wong, K.A. Getman, C., Stein, N., Cheng, G., Wu, H., and Shuai K. (2005) Negative Regulation of NF-kB signaling by PIAS1. Mol. Cell Biol. 25:1113-23. PMCID: PMCID: 544018
121. Wu, H., Khodavirdi, A., and Roy-Burman, P (2005) Capturing Signal Anomalies of Human Prostate Cancer into Mouse Models. Chapter in “Prostate Cancer: Basic Mechanisms and Therapeutic Approaches” World Scientific Publishing Co. 393-421.
122. Kurlawalla-Martinez, C., Stiles, B., Wang, Y., Devaskar, S., Kahn, B., and Wu, H. (2005) Insulin Hypersensitivity and Resistance to Streptozotocin Induced Diabetes in Mice Lacking PTEN in Adipose Tissue Mol. Cell Biol. 25:2498-510. PMCID: PMC1061603
123. Lim, M. A., Moon, S. Y., Zheng, Y., Wu, H., Dong, L. Q., and Liu, F. (2004) Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation in PTEN-deficient cells. Oncogene 1-11. PMID:15531926
124. Liu, B., Mink. S., Wong, K.A., Stein, N., Getman, C., Dempsey, P., Wu, H., Shuai, K. (2004) PIAS1 Selectively Inhibits a Subset of IFN-Inducible Genes and Is Important in Innate Immunity. Nature Immunology 5:891-898. PMID:15311277
125. Kertesz, N., Wu, J., Chen, T., Sucov, H. and Wu, H. (2004) The role of erythropoietin in regulating angiogenesis. Devel. Biol. 276: 101-110. PMID:15531367
126. Stiles, B., Groszer, M., Wang, S., Jiao, J. and Wu, H (2004) PTENless means more. Devel. Biol. 273:175-184. PMID:15328005
127. Johnson, J.D., Han, Z., Otani, K., Ye H., Zhang, Y., Wu, H., Horikawa, Y., Misler, S., Bell, G.I., Polonsky, K.S. (2004) RyR2 and Calpain-10 Delineate a Novel Apoptosis Pathway in Pancreatic Islets. J. Biol. Chem. 279: 24794-24802. PMID:15044459
128. Chang, Chun-ju, Freeman, D. and Wu, H. (2004) PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 279:29841-29848. PMID:15090541
129. Wong, K., Kim, R., Christofk, H., Gao, J. and Wu, H. (2004) Protein inhibitor of activated STAT Y (PIASy) enhances sumoylation but is not essential for embryogenesis and adult life. Mol. Cell Biol. 12:5577-5586. PMCID: PMC419860
130. Roy-Burman P., Wu, H., Powell, W.C. Hagenkord, J., and Cohen, M.B. (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocrine-Related Cancer 11:225-254. PMID:15163300
131. Stiles, B., Wang, Y., Stahl, A., Bassilian, S., Lee, W.P., Kim, Y-J., Sherwin R., Devaskar, S., Lesche, R., Magnuson, M., and Wu, H. (2004) Live-Specific Deletion of negative regulator Pten Results in Fatty Liver and Insulin Hypersensitivity. Proc. Natl. Acad. Sci. USA 101: 2082-2087. PMCID: PMC357055
132. Sundaresan G., Paulmurugan R., Berger, F., Stiles, B., Nagayama, Y., Wu, H., and Gambhir, S. (2004) MicroPET Imaging of Cre-loxP Mediated Conditional Activation of a Herpes Simplex Virus Type I Thymidine Kinase Reporter Gene. Gene Ther. 7: 609-618. PMID:14724687
133. Wang, S., Gao, J., Lei, Q-Y., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G., Li, G., Roy-Burman, P., Nelson, P., Liu, X., and Wu, H. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221. PMID: 14522255
134. Tsai, P., Lee, R.A., and Wu, H., (2003) BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 102:3947-3953. PMID:12920023
135. Wong, K., Tsai, P., Jegalian, A., Kertesz, N., Lee, R. and Wu, H. (2003) Erythropoietin, Biochemistry of. In Encyclopedia of Hormones Academic Press 561-569.
136. Anzelon, A., Wu, H., and Rickert R. (2003) Pten Inactivation Alters Peripheral B Lymphocyte Fate and Reconstitutes CD19 Function. Nature Immunology 4:287-294. PMID:12563260
137. Freeman, D., Wei, G., Li, H., Li, A., Lesche, R., Whale, A., Martinez-Diaz, H., Rozengurt, N., Liu, X. and Wu, H. (2003) PTEN Tumor Suppressor Gene Regulates p53 Through Both MDM2-Dependent and Independent Mechanisms. Cancer Cell 3:117-129.
138. Kertesz, N., Samson, j., Debacker, C., Wu, H. and Labastie, M-C. (2002) Cloning and Characterization of Human and Mouse SNRK SNF-1 Related Kinases. Gene 294:13-24. PMID: 12234663
139. Osawa, M., Yamaguchi, T., Nakamura, Y., Kaneko, S., Onodera, M., Sawada, K-I., Jegalian, A., Wu, H., Nakauchi, H., Iwama, A. (2002) Erythroid Expansion Mediated by the Gfi-1B Zinc Finger Protein: Role in Normal Hematopoiesis. Blood 100:2769-2777. PMID:12351384
140. Li, G., Robinson, G.W., Lesche, R., Martinez-Diaz, H., Jiang, Z.R., Rozengurt, N., Wagner, K., Wu, D.C., Lane, T.F., Liu, X., Hennighausen, L., and Wu, H. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129:4159-4170. PMID:12163417
141. Jegalian, A. and Wu, H. (2002) Differential roles of SOCS family members in EpoR signal transduction. J. Cyto.Research 22:853-860.
142. Stiles, B., Gilman, V., Khnzenzon, N., Lesche, R., Li, A., Qiao, R., Liu, X., and Wu, H. (2002) The Essential Role of AKT-1/PKB in PTEN Controlled Tumorigenesis. Mol. Cell. Biology 22: 3842-3851. PMCID: PMC133830
143. Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Liu, X., and Wu, H. (2002) Cre/loxp-Mediated Inactivation of The Murine Pten Tumor Suppressor Gene. Genesis 32: 148-149. PMID: 11857804
144. Jegalian, A., Acurio, A., Dranoff, G., Wu, H. (2002) Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukine 3. Blood 99:2603-2605. PMID:11895800
145. Jegalian, A. and Wu, H. (2002) Regulation of SOCS gene expression by the proto-oncogene Gfi-1B: Two Routes for STAT5-Target Gene Induction by Erythropoietin. J. Biol. Chem. 277: 2345-2352. PMID:11696536
146. Hisakawa, H., Sugiyama, D., Nishijima, I., Wu, H., Nakao, K., Watanabe, S., Katsuki, M., Asano, S., Arai, K., Nakahata, T., Tsuji, K. (2002) Human Granulocyte-Macrophage Colony-Stimulating Factor (hGM-CSF) Stimulates Primitive and Definitive Erythropoiesis in Mouse Embryo Expressing hGM-CSF Receptors but not Erythropoietin Receptors. Blood 98: 3618-3625. PMID:11739165
147. Groszer, M., Erickson, R., Scripture-Adams, D., Lesche, R., Trumpp, A., Zack, J., Kornblum, H., Liu, X., and Wu, H. (2001) Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the Pten Tumor Suppressor Gene In Vivo. Science 294: 2186-2189. PMID:11691952
148. Neshat, M., Mellinghoff, I., Tran, C., Stiles, B., Thomas, G., Wu, H., and Sawyers, C. (2001) Enhanced sensitively of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98: 10314-10319. PMCID: PMC56958
149. Lee, R., Kertesz, N., Joseph, S., Jegalian, A. and Wu, H. (2001) Erythropoietin (Epo) and EpoR Expression and Two Waves of Erythropoiesis. Blood 98: 1408-1415.
150. Dubey, P., Wu, H., Reiter, R. and Witte, O. (2001) Alternative Pathways to Prostate Carcinoma Activated PSCA Expression. Cancer Research 61: 3256-3261.PMID:11309275
151. Mamillapalli, R., Gavrilova, N., Mihaylova, V., Tsvetkov, L. Wu, H., Zhang, H. and Sun H. (2001) PTEN Regulates The Ubiquitin-Dependent Degradation Of The Cdk Inhibitor P27kip1 Through The Ubiquitin E3 Ligase Scfskp2 Current Biology 11, 263-267. PMID:11250155
152. Makita, T., Hernandez-Hoyos, G., Chen, T., Wu, H., Rothenberg, E. and Sucov, H (2001) A Developmental Transition in Definitive Erythropoiesis Controlled by Competitive Regulation of Erythropoietin Expression by Retinoid Acid Receptor and HNF4. Gene & Devel. 15:889-901. PMCID: PMC312661
153. Statterthwaite, A., Willis, F., Kanchanastit, P., Cantley, L., Fruman D., Humphries, K., Lesche, R., Lowell, C., Perlmutter, R., Simon, M., Tarakhovsky, A., Tedder, T., Wu, H. and Witte, O. (2000) A sensitized Genetic System for the Analysis of Murine B Lymphocyte Signal Transduction Pathways Dependent on Bruton’s Tyrosine Kinase. Proc. Natl. Acad. Sci. USA 97, 6687-6692. PMCID: PMC18703
154. Liliental,J., Lesche, R., Moon, S-Y., Mamillapalli, R., Gavrilova, N., Sun, H., Zheng, Y., and Wu, H. (2000) Genetic Deletion of the Pten Tumor Suppressor Gene Promotes Cell Motility by Activation of Rac1 and Cdc42 GTPases. Current Biology 10,401-404. PMID:10753747
155. Ghaffari, S., Wu, H., Gerlach, M., Han, Y., Lodish, H. and Daley, G. (1999) BCR-ABL and v- SRC Tyrosine Kinase Oncoproteins Support Normal Erythroid Development in Erythropoietin Receptor-Deficient Progenitor Cells. Proc. Natl. Acad. Sci. USA 96, 13186-13190. PMCID:PMC 23922
156. Wu, H., Lee, S-H, Gao, J., Liu, X. and Iruela-Arispe, L. (1999) Inactivation of Erythropoietin Leads to Defects in Cardiac Morphogenesis. Development 126:3597-3605. PMID:10409505
157. Sun, H., Lesche, R., Li, DM., Liliental, J., Zhang, H., Gao, J., Garvarina, N., Mueller, B., Liu, X. and Wu, H. (1999) PTEN Modulates Cell Cycle Prograssion and Cell Survival by Regulating PIP3 and AKT/PKB Signaling Pathway. Proc. Natl. Acad. Sci. USA 96: 6199-6204. PMCID: PMC26859
158. Neubauer, H, Cumano, A., Muller, M., Wu, H., Huffstadt, U. and Pfeffer, K. (1998) Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis. Cell 93, 397-409. PMID:9590174
159. Constantinescu, S., Wu, H. Liu, X-D, Beyer, W., Fallon, A and Lodish, H.F. (1998) The Anemic Friend Virus gp55 Envelope Protein Induces Erythroid Differentiation in Fetal liver Colony-Forming-Units-Erythroid. Blood 91, 1163-1172. PMID:9454745
160. Klingmuller, K., Wu, H., Hsiao, J., Duckworth, B., Toker, A., Cantley, L.C. and Lodish, H.F. (1997) Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc. Natl. Acad. Sci. USA 94, 3016-3021. PMCID: PMC20314
161. Liu, X., Wu, H., Loring, J., Hormuzdi, S., Disteche, C. M., Bornstein, P. and Jaenisch, R. (1997) Trisomy eight in ES cells is a common potential problem in gene targeting and interferes with germ line transmission. Developmental Dynamics 209, 85-91. PMID:9142498
162. Wu, H., Klingmüller, U., Acurio, A., Hsiao, J. G. and Lodish, H. F. (1997) Functional Interaction of Erythropoietin and Stem Cell Factor Receptors is Essential for Erythroid Colony Formation. Proc. Natl. Acad. Sci. USA. 94, 1806-1810. PMCID: PMC19998
163. Liu, X., Wu, H. and Jaenisch, R. (1997). Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc. Natl. Acad. Sci. USA 94, 1852-1856.PMCID: PMC 20006
164. Wu, H. and Lodish, H.F. (1996) The erythropoietin receptor: dimerization and intracellular signal transduction. Journal of Experimental Hematology. 4, 229-235.
165. Watowich, S.S., Wu, H., Socolovsky, M., Klingmuller, U., Constantinescu, S.N. and Lodish, H.F. (1996). Cytokine receptor signal transduction and the control of hematopoietic cell development. Ann. Rev. Cell. Devel. 12, 91-128. PMID:8970723
166. Byrne, M., Eeckhout, Y., Henriet, P., Lemaǐtre, V., Jeffrey, J.J., Witter, J., Liu, X., Wu, H., Jaenisch, R. and Krane, S.M. (1996). Different collagenase gene products have different roles in remodeling of type I collagen-containing extracellular matrices. J. Biol. Chem. 271, 28509-28515. PMID:8910479
167. Iruela, M.L., Vernon, R.B., Wu, H., Jeanisch, R. and Sage H. (1996). Type I collagen is required for the association of SPARC with the extracellular matrix in Mov-13 mice: implications for fibroblast function. Developmental Dynamics 207, 171-183.
168. Lodish, H., Hilton, D., Klingmuller, U., Watowich, S. and Wu, H. (1995). The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harbor Symp, LX, 93-104. PMID:8824381
169. Wu, H., Liu, X., Jaenisch, R. and Lodish, H. (1995). Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 59-67. PMID:7553874
170. Wu, H., Klingmüller, U., Besmer, P. and Lodish, H. (1995). Interaction of the erythropoietin and stem cell factor receptors. Nature 377, 242-246. PMID:7545788
171. Liu, X., Enfors, P., Wu, H. and Jaenisch, R. (1995). Mice lacking NT-4 or both NT-4 and BDNF develop with sensory neuron deficit, but show no motor neuron loss. Nature 375, 238-241.
172. Liu, X., Wu, H., Byrne, M., Jeffrey, J., Krane, S. and Jaenisch, R. (1995) A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J. Cell. Biol. 130, 227-237. PMCID: PMC2120510
173. Wu, H., Liu, X. and Jaenisch, R. (1994) Double replacement: strategy for efficient introduction of subtle mutations into the murine Col1a-1 gene by homologous recombination in embryonic stem cells. Proc. Natl. Acad. Sci. USA 91, 2819-2823. PMCID:PMC43462
174. Dzamba, B. J., Wu, H., Jaenisch, R. and Peters, D. M. (1993) Fibronectin binding site in type I collagen regulates fibronectin fibril formation. J. Cell. Biol. 121(5), 1165-1172. PMCID:PMC2119696
175. Hasty, K., Wu, H., Byrne, M., Goldring, M., Jaenisch, R., Krane, S. and Mainardi, C. (1993). Susceptibility of type I collagen containing mutated alpha1 (I) chains to cleavage by human neutrophil collagenase. Matrix 13(3), 181-186. PMID:8326908
176. Wu, H., Faessler, R., Schnieke, A., Barker, D., Chapman, V., Francke, U. and Jaenisch, R. (1992). A X-linked human collagen transgene escapes X inactivation in a subset of cells. Development 116: 687. PMID:1289060
177. Barker, D., Wu, H., Hartung, S., Breindl, M. and Jaenisch, R. (1991). Retrovirus induced insertional mutagenesis: Mechanism of collagen mutation in Mov13 mice. Mol. Cell. Biology 11: 5154-5163. PMCID:PMC361539
178. Wu, H., Byrne, M.H., Stacey, A., Goldring, M.B., Birkhead, J.R., Jaenisch, R. and Krane, S.M. (1990). Generation of collagenase resistant collagen by site-directed mutagenesis of murine pro1 (l) collagen gene. Proc. Natl. Acad. Sci. U.S.A 87, 5888-5892. PMCID:PMC54434
179. Wu, H., Bateman, J.F., Schnieke, A., Sharpe, A., Barker, D., Mascara, T., Eyre, D., Bruns, R., Krimpenfort, P., Berns, A. and Jaenisch, R (1990). Human-mouse interspecies collagen I heterotrimer is functional during embryonic development of Mov13 mutant mouse embryos. Mol. Cell. Biology 10: 1452-1460. PMCID:PMC362247
180. Silverman, D., Wu, H. and Karnovsky, M. (1985). Muramyl peptides and serotonin interact at specific binding sites on macrophages and enhance superoxide release. Biochem & Biophys. Res. Comm 131:1160-1167. PMID:2996538

Laboratory Introduction